Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

– First oral therapy to demonstrate efficacy and safety for uterine fibroids in two U.S. pivotal studies – VENUS II study reinforces efficacy, safety seen in VENUS I study, meeting all co-primary and secondary endpoints